Project Grant R01CA301637
Award Date
6/1/25
Completion Date
4/30/30
Dollars Obligated
$684K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
미국 뉴욕
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) to Weill Medical College of Cornell University provides $710,980 over 5 years starting on Aug 1, 2024 to support research on the SPOP ubiquitin signaling pathway in prostate cancer. The project aims to: 1) Define the role of the upstream regulator G3BP1 in driving prostate tumorigenesis and the ability to target this axis, and 2) Establish the therapeutic potential of modulating the SPOP signaling...
This federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $564,543 to Weill Medical College of Cornell University to conduct research on the role of the androgen receptor (AR) in prostate cancer. The key objectives are to: Determine the context that allows engagement of the growth-suppressive AR transcriptional program in prostate cancer, Establish the translational implications of oncogenic and growth-suppressive AR...
The National Cancer Institute awarded a $392,410 Project Grant (CFDA 93.398 Cancer Research Manpower) to Weill Medical College of Cornell University to conduct research aimed at understanding the drivers of tumor heterogeneity and the progression to neuroendocrine prostate cancer (NEPC). The three-year grant, which begins on July 1, 2024 and runs through June 30, 2027, will support the development of an organoid-based allograft platform to modulate the expression of a key transcriptional...
This Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) provides $509,246 to the Regents of the University of Michigan to conduct research aimed at understanding the early drivers of prostate cancer lineage plasticity. The research seeks to identify key transcriptional regulators that block androgen receptor signaling and promote alternate differentiation programs in prostate tumors, leading to more aggressive disease phenotypes. The three-year project...
This National Cancer Institute (NCI) Project Grant award under CFDA 93.395 "Cancer Treatment Research" provides $415,902 to the University of Massachusetts Boston to conduct research on overcoming therapy resistance in castration-resistant prostate cancer. The key objectives are to: Determine if expression of the transcription factor FOXA2 can drive prostate cancer cells into a multi-lineage transition state, enabling therapy resistance. Investigate how FOXA2 interacts with the AP-1...
This $312,610 federal Project Grant was awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant supports advanced biomedical research at Weill Medical College of Cornell University focused on the "Role of Functional Factors in AR Reprogramming and Progression of Prostate Cancer." The 2-year grant, running from September 2024 to September 2026, will fund cutting-edge investigations into the cellular mechanisms driving...
The National Cancer Institute awarded Emory University a 5-year, $1,082,472 Project Grant (CFDA 93.395 - Cancer Treatment Research) to determine the molecular mechanisms underlying the transition of prostate adenocarcinoma to the lethal neuroendocrine prostate cancer subtype. The research aims to characterize how the transcription factor FOXA2 interacts with NKX2-1 to drive this transdifferentiation process, involving changes in DNA methylation, chromatin remodeling, and 3D genome...
The National Cancer Institute awarded a $633,705 Project Grant (CFDA 93.395 - Cancer Treatment Research) to Mayo Clinic to investigate mechanisms underlying resistance to PARP inhibitor (PARPI) drugs in prostate cancer. The research aims to identify strategies to overcome PARPI resistance, which is a significant challenge in treating metastatic castrate-resistant prostate cancer (mCRPC). The award supports a 5-year project (12/11/2024 - 11/30/2029) focused on three key objectives: 1) examining...
This $1,518,817 federal Project Grant award, provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports research conducted by Weill Medical College of Cornell University to characterize the role of 3'-UTR biology as a mechanism of therapy response in high-risk prostate cancer. The research aims to advance understanding of the cellular processes underlying therapy resistance in aggressive prostate cancer, with the goal of developing...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) is supporting research to develop a novel gene therapy approach to target the oncogenic transcription factor HOXB13 and inhibit metastatic castration-resistant prostate cancer (mCRPC). The $636,289 award to Duke University, with sub-awards to the Medical College of Wisconsin and Icahn School of Medicine at Mount Sinai, aims to uncover the molecular mechanisms by which HOXB13 drives mCRPC...